RNU6-126P

Across TCGA pan-cancer cohorts, RNU6-126P RNA differs between tumor and matched normal tissue in 10 of 18 cancer types tested, making tumor–normal expression one of RNU6-126P’s most consistent transcriptional readouts.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where RNU6-126P RNA is more highly expressed in tumor relative to normal tissue. In most cancer types RNU6-126P is over-expressed in tumor.

KIRC, LUSC, and STAD are the cancer types where RNU6-126P tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in RNU6-126P RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
KIRC	Male	II,III,IV	+0.250	<.001	6	view →
LUSC	All	II,III,IV	+0.568	<.001	5	view →
STAD	All	All	+0.573	.010	4	view →
KICH	All	All	+0.185	.012	3	view →
CHOL	All	II,III,IV	+0.765	<.001	2	view →
BLCA	All	All	+0.396	.034	2	view →
COAD	Male	All	+0.347	.035	2	view →
PRAD	All	All	+0.263	.029	2	view →
LUAD	Male	All	+0.624	.042	1	view →
LIHC	Male	All	+0.092	.044	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 10 strongest of 10 lineages.

RNU6-126P–KIRC

Open the KIRC breakdown →